2016
DOI: 10.18632/aging.100981
|View full text |Cite
|
Sign up to set email alerts
|

Reversal of cognitive decline in Alzheimer's disease

Abstract: Alzheimer's disease is one of the most significant healthcare problems nationally and globally. Recently, the first description of the reversal of cognitive decline in patients with early Alzheimer's disease or its precursors, MCI (mild cognitive impairment) and SCI (subjective cognitive impairment), was published [1]. The therapeutic approach used was programmatic and personalized rather than monotherapeutic and invariant, and was dubbed metabolic enhancement for neurodegeneration (MEND). Patients who had had… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

2
111
0
8

Year Published

2016
2016
2023
2023

Publication Types

Select...
6
4

Relationship

0
10

Authors

Journals

citations
Cited by 130 publications
(121 citation statements)
references
References 17 publications
2
111
0
8
Order By: Relevance
“…In the five case studies only three provided pre-post-test MMSE or similar which hindered comparison of clinical importance (Figure 4). The case studies in Bredesen et al (2016) reported over 10 instruments including magnetic resonance imaging (MRI) and fluorodeoxyglucose (FDG)-positron emission tomography (PET) scans, metabolic testing, quantitative neuropsychological testing, genetic testing and a battery of cognitive tests. Whilst three of these case studies reported pre-post-test MMSE, one (Patient 9) reported the Montreal Cognitive Assessment (MoCA) instead, which substituted for the MMSE in the ES analysis.…”
mentioning
confidence: 99%
“…In the five case studies only three provided pre-post-test MMSE or similar which hindered comparison of clinical importance (Figure 4). The case studies in Bredesen et al (2016) reported over 10 instruments including magnetic resonance imaging (MRI) and fluorodeoxyglucose (FDG)-positron emission tomography (PET) scans, metabolic testing, quantitative neuropsychological testing, genetic testing and a battery of cognitive tests. Whilst three of these case studies reported pre-post-test MMSE, one (Patient 9) reported the Montreal Cognitive Assessment (MoCA) instead, which substituted for the MMSE in the ES analysis.…”
mentioning
confidence: 99%
“…Our previous work using a similar herbal formula called GAPT can markedly enhance learning and memory of AD rat models induced by Aβ injection or transgenic mice of APPV717I and APPs we/PS1dE9 [13], and also showed a significant improvement on cognitive function in patients with amnestic mild cognitive impairment, an early stage of AD (n = 101), consistently across different cognitive cales in a small sample of clinical trial [14]. The good effects of multiple combined therapy in treating MCI (mild cognitive impairment) and SCI (subjective cognitive impairment) and AD, was published by Dale E. Bredesen et al [15] [16]. A therapeutic approach characterized by programmatic, personalization, as well as dubbed metabolic enhancement for neurodegeneration (MEND protocol) was used.…”
Section: Discussionmentioning
confidence: 90%
“…There is now a growing awareness that comprehensive management of ill health requires multiple approaches including management of lifestyle factors. An example of the preliminary data showing signs of success using multiple approaches is the reversal of the cognitive decline in people with Alzheimer's and cognitive impairment, which includes an individualized, iterative, multi-pronged program including optimising biomarkers, nutritional supplements, fasting, exercise, brain stimulation, stress reduction and sleep optimization [81,82].…”
Section: Discussionmentioning
confidence: 99%